BioAge Misled on Weight Loss Trial Before IPO, Investor Alleges

A biopharmaceutical company and its executives misled investors ahead of its 2024 initial public offering about a key clinical weight-loss drug trial that was ended by liver damage concerns, sending the stock down 77%, a proposed class action filed Tuesday said.

BioAge Labs, Inc.'s September IPO registration statement had projected an air of safety regarding the phase 2 trial, including that it expected “topline results in the third quarter of 2025" and was entering a collaboration with a reputable pharmaceutical company, investor Celia Soto claimed in the complaint filed in the US District Court for the Northern District of California. ...